January 7, 2020Medical Science MonitorOpen Access

The combination of MPVLR and PIA effectively predicted no-reflow phenomenon (AUC=0.847, 95% CI: 0.821-0.874) and 90-day mortality (AUC=0.790, 95% CI: 0.725-0.855).

View Full Paper

Ask AI

Bookmark

Why the study?

The clinical predictive value of pre-infarction angina combined with mean platelet volume to lymphocyte count ratio for no-reflow and short-term mortality in STEMI patients undergoing PCI required investigation.

Does the combination of pre-infarction angina and mean platelet volume to lymphocyte count ratio predict no-reflow and 90-day mortality in STEMI patients undergoing PCI?

Population

1009 STEMI patients who had undergone PCI

Comparison

4 groups based on occurrence of PIA and MPVLR above or below cutoff

Design

Cohort study

Follow-up

90 days

Authors

XCXinsen Chen YMYoubao Meng MSMeng Shao

Discussion

Member takes

Overview

May support risk stratification in STEMI PCI; hypothesis-generating and requires prospective validation before practice change.

Structured PICO

Does the combination of pre-infarction angina and mean platelet volume to lymphocyte count ratio predict no-reflow and 90-day mortality in STEMI patients undergoing PCI?

Population

1009 patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI)

Intervention

Pre-infarction angina (PIA) combined with mean platelet volume to lymphocyte count ratio (MPVLR)

Comparator

Patients grouped by presence/absence of PIA and MPVLR above/below cutoff

Outcome

No-reflow phenomenon and 90-day mortalityhard clinical

The combination of pre-infarction angina and MPVLR provides a strong predictive value for no-reflow and short-term mortality in STEMI patients undergoing PCI.

Cite This Study

Chen et al. (2020) studied this question.

synapsesocial.com/papers/6a8a3ad441f4089922bd87af https://doi.org/10.12659/msm.919300

View Full Paper

Ask AI

Bookmark

January 7, 2020Medical Science MonitorOpen Access

The combination of MPVLR and PIA effectively predicted no-reflow phenomenon (AUC=0.847, 95% CI: 0.821-0.874) and 90-day mortality (AUC=0.790, 95% CI: 0.725-0.855).

View Full Paper

Ask AI

Bookmark

Why the study?

Does the combination of pre-infarction angina and mean platelet volume to lymphocyte count ratio predict no-reflow and 90-day mortality in STEMI patients undergoing PCI?

Population

1009 STEMI patients who had undergone PCI

Comparison

4 groups based on occurrence of PIA and MPVLR above or below cutoff

Design

Cohort study

Follow-up

90 days

Authors

XCXinsen Chen YMYoubao Meng MSMeng Shao

Discussion

Member takes

Overview

May support risk stratification in STEMI PCI; hypothesis-generating and requires prospective validation before practice change.

Structured PICO

Does the combination of pre-infarction angina and mean platelet volume to lymphocyte count ratio predict no-reflow and 90-day mortality in STEMI patients undergoing PCI?

Population

1009 patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI)

Intervention

Pre-infarction angina (PIA) combined with mean platelet volume to lymphocyte count ratio (MPVLR)

Comparator

Patients grouped by presence/absence of PIA and MPVLR above/below cutoff

Outcome

No-reflow phenomenon and 90-day mortalityhard clinical

The combination of pre-infarction angina and MPVLR provides a strong predictive value for no-reflow and short-term mortality in STEMI patients undergoing PCI.

Cite This Study

Chen et al. (2020) studied this question.

synapsesocial.com/papers/6a8a3ad441f4089922bd87af https://doi.org/10.12659/msm.919300

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark